Generex Oncology Granted United States Patent for AE37 Peptide Vaccine
The AE37 immunotherapeutic vaccine is being developed by Antigen Express, Generex’s wholly-owned subsidiary, for use in patients with HER2 positive cancers. The vaccine is the subject of a randomized and controlled Phase II trial in patients with breast cancer; positive interim results, showing reduced relapse rates in patients receiving AE37, were released late in 2009. A Phase I trial of AE37 in patients with prostate cancer has been completed recently. A Phase I trial of AE37 in combination with another peptide vaccine is underway in patients with breast or ovarian cancer.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.